Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2021-02-05 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
주요사항보고서(유형자산양도결정)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange by JW Pharmaceutical. It details a specific corporate decision regarding the disposal of tangible assets (real estate). This type of regulatory filing, which reports a significant corporate event or transaction, falls under the 'Regulatory Filings' category as it is a mandatory disclosure of a material event that does not fit into more specific categories like M&A or share issuance.
2021-02-05 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from JW Pharmaceutical regarding a 'Bonus Issue' (무상증자결정). In the context of Korean corporate filings, a bonus issue (free share issuance) is a capital change event. Since the document details the specific allocation of new shares, the source of funds (share premium), and the impact on total shares, it falls under the category of share issuance and capital changes.
2020-12-16 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for JW Pharmaceutical for the period ending September 30, 2020. It contains comprehensive financial statements, management discussion, and operational details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Report' (영업(잠정)실적) from JW Pharmaceutical. It provides a summary table of key financial metrics (revenue, operating profit, net income) for the 3rd quarter of 2020 compared to previous periods. This is a standard initial announcement of quarterly financial results, which fits the definition of an Earnings Release (ER). Q3 2020
2020-11-05 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for JW Pharmaceutical, covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial information, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical detailing their 'Compliance Program' (CP) operational status and future plans. It is a periodic disclosure of internal governance and compliance activities, which does not fit into specific categories like financial reports, M&A, or shareholder voting. Therefore, it is classified as a general regulatory filing (RNS).
2020-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.